Harrison Kordestani
Directeur Général chez RICH PHARMACEUTICALS, INC.
Profil
Harrison Kordestani is currently the Chief Executive Officer & Director at Rich Pharmaceuticals, Inc. and also holds a position as Manager-Finance, Acquisitions & Production at Arclight Films Pty Ltd.
Previously, he worked as a Compliance Officer at Geopulse Exploration, Inc.
Postes actifs de Harrison Kordestani
| Sociétés | Poste | Début |
|---|---|---|
| RICH PHARMACEUTICALS, INC. | Directeur Général | 29/06/2021 |
Arclight Films Pty Ltd.
 Arclight Films Pty Ltd. Movies/EntertainmentConsumer Services Arclight Films produces and distributes motion pictures. It focuses on international film sales and distribution services. The company has offices in Los Angeles, New York, London, Sydney, Melbourne, Toronto, and Hong Kong. The firm was founded by Victor Syrmis and Gary Hamilton in 2002 and is located in North Sydney, Australia. | Directeur Financier/CFO | - |
Anciens postes connus de Harrison Kordestani
| Sociétés | Poste | Fin |
|---|---|---|
| GEOPULSE EXPLORATION, INC. | Compliance Officer | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| GEOPULSE EXPLORATION, INC. | Commercial Services |
| Entreprise privées | 2 |
|---|---|
Arclight Films Pty Ltd.
Arclight Films Pty Ltd. Movies/EntertainmentConsumer Services Arclight Films produces and distributes motion pictures. It focuses on international film sales and distribution services. The company has offices in Los Angeles, New York, London, Sydney, Melbourne, Toronto, and Hong Kong. The firm was founded by Victor Syrmis and Gary Hamilton in 2002 and is located in North Sydney, Australia. | Consumer Services |
Rich Pharmaceuticals, Inc.
 Rich Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Rich Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages on developing innovative therapies in oncology. It develops RP-323 for the treatment of Hodgkin’s lymphoma, Acute Myelogenous Leukemia, and to cause elevation of white blood cells in patients depleted of these elements due to various conditions. The company was founded on August 9, 2010 and is headquartered in Beverly Hills, CA. | Health Technology |
